News & Updates

Show Multimedia Only

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025 by

New research indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer a protective effect against cancers in adults with overweight or obesity regardless of type 2 diabetes status.

GLP1-RAs help fight cancers in adults with overweight, obesity

03 Sep 2025

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025 by

The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

03 Sep 2025

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Receiving a stimulant prescription for attention deficit hyperactivity disorder (ADHD) via telehealth shows no significant impact on the risk for substance use disorder (SUD) but appears to elevate the risk of subsequent stimulant use disorder (stimUD), suggests a study.

Does telehealth prescribing raise risk of substance use disorder?

03 Sep 2025

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

Treatment with antipsychotics may lead to a significant glucose homeostasis dysregulation, regardless of exposure time, dose, diagnosis, and weight gain propensity, according to systematic review and meta-analysis.

Antipsychotic drugs tied to glucose homeostasis disruption

03 Sep 2025

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Patients with type 2 diabetes mellitus (T2DM) who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lower odds of peptic ulcer disease when compared with insulin users, as shown in a retrospective study.

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025 by

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025

Desensitization feasible in patients with HSRs to chemotherapy

02 Sep 2025

Total dose desensitization is successful in patients with hypersensitivity reactions (HSRs) to chemotherapy, suggests a study.

Desensitization feasible in patients with HSRs to chemotherapy

02 Sep 2025

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

02 Sep 2025 by

The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

02 Sep 2025

Does aprepitant influence response to DICEP?

02 Sep 2025

A recent study in Canada has shown similar response rates to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) in patients with relapsed/refractory Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) regardless of aprepitant use.

Does aprepitant influence response to DICEP?

02 Sep 2025

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

02 Sep 2025 by

Patients labelled as allergic to penicillin or other beta-lactam antibiotics face a significantly higher risk of periprosthetic joint infection (PJI) up to 5 years following knee arthroplasty, and should be prioritized for preoperative allergy assessment, researchers from the University of Hong Kong (HKU) have found.

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

02 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

GLP1-RAs help fight cancers in adults with overweight, obesity

GLP1-RAs help fight cancers in adults with overweight, obesity

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer

Does telehealth prescribing raise risk of substance use disorder?

Does telehealth prescribing raise risk of substance use disorder?

Antipsychotic drugs tied to glucose homeostasis disruption

Antipsychotic drugs tied to glucose homeostasis disruption

GLP-1 RA use in T2DM may protect against peptic ulcer disease

GLP-1 RA use in T2DM may protect against peptic ulcer disease

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Desensitization feasible in patients with HSRs to chemotherapy

Desensitization feasible in patients with HSRs to chemotherapy

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

Does aprepitant influence response to DICEP?

Does aprepitant influence response to DICEP?

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service